HOME >> MEDICINE >> NEWS
Oral formulation of antipsychotic offers 'user-friendly' alternative to injections for patients with acute psychosis

[11 September 2000, Munich] -- Although many physicians rely on intramuscular injections of antipsychotic drugs to treat patients who need emergency treatment for psychotic agitation, new research has found that the oral-solution form of Risperdal™ (risperidone) is just as effective and may be a more acceptable alternative for both caregivers and patients(1).

The study, which was presented today at a major international neuropsychopharmacology congress in Munich, found that Risperdal works as quickly and is as effective in reducing symptoms of psychotic agitation as an intramuscular (IM) injection of haloperidol, an older, conventional antipsychotic. Both medications were administered in combination with the antianxiety drug lorazepam.

"When there are two drugs that are equally efficacious, a physician's next consideration when selecting an antipsychotic drug in emergency situations should be patient choice and compliance," said Dr Glenn Currier, lead investigator and assistant professor of the departments of psychiatry and emergency medicine at the University of Rochester. "When patients experiencing psychotic agitation -- usually due to schizophrenia -- end up in the emergency room, they often are confused, scared and paranoid. Injections are painful, and can be perceived as hostile and 'coercive.' This can be a significant barrier to the physician's ability to deliver good care, and to the patient's ability to accept it."

In contrast, an oral solution (liquid) is more easily administered in emergency situations than pills, and is non-invasive. Patients also can continue on the same medication when they leave the hospital, which encourages long-term compliance. Dr. Currier adds that an oral-solution formulation offers benefits to caregivers as well. Injections expose staff members at hospitals and other facilities to an increased risk of needlepricks and a resultant exposure to diseases such as AIDS and hepatitis -- especially w
'"/>

Contact: John Gisborne
john.gisborne@ketchumcomms.co.uk
44-207-465-8753
Ketchum
10-Sep-2000


Page: 1 2 3

Related medicine news :

1. Newer formulation of heparin improves outcomes for suspected heart attack patients
2. Newer vitamin D formulation appears to help dialysis patients live longer
3. Bristol-Meyers Squibb submits NDA for new formulation of once daily videx(R)(didanosine)
4. Researchers warn antipsychotic drug
5. New antipsychotic drugs combined with nicotine patch help schizophrenics quit smoking
6. New study shows prescribing of newer antipsychotic medication risperdal may save millions in schizophrenia care
7. UCSF study offers insight into human circadian rhythms
8. Research offers hope of new treatments for liver damage
9. Portable system offers dialysis patients liberating changes
10. New laparoscopic hysterectomy offers quicker recovery time than traditional surgery
11. UIC offers new weight loss surgery for obese teens

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/9/2016)... ... December 09, 2016 , ... Mediaplanet today announces distribution of the latest ... readers to sign up as an organ donor for the 123,000 people in the ... organ donor can save up to 8 saves through organ donation and enhance many ...
(Date:12/9/2016)... ... December 09, 2016 , ... The Pennsylvania Athletic Trainers’ Society ... the summer of 2016. The program was made possible by a Pennsylvania Department ... of Health and Human Services Administration. The broadcast, Use Your Head: Properly ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... Donuts Franchising Company LLC, announced the first national #QuackGivesBack campaign which supported ... , “This was our first franchise-wide Quack Gives Back initiative, and ...
(Date:12/8/2016)... ... December 08, 2016 , ... CURE Media Group, the nation’s ... groups, has aligned with Upstage Lung Cancer in efforts to combat lung cancer, announced ... J. Hennessy, Jr said, “CURE Media Group is honored to team up with Upstage ...
(Date:12/8/2016)... Tampa, Fla (PRWEB) , ... December 08, 2016 ... ... offering smarter modes of access for customers and employees that are both engaging ... ChangeGear 7 with Service Smart Technology, the software company revealed today its plans ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... Mass. , Dec. 8, 2016   ... that Nationwide Children,s Hospital signed a ... and accelerate the development of new cures. ... organizations representing over 57 million patients globally, biopharmaceutical ... working together to improve protocol design, site selection, ...
(Date:12/8/2016)... 2016  Valeant Pharmaceuticals International, Inc. (NYSE: ... announced positive results from a Phase 3, multicenter ... safety and efficacy of IDP-118 (halobetasol propionate and ... Within the Phase 3 study ... psoriasis, IDP-118 showed statistical significance to vehicle with ...
(Date:12/8/2016)... , Dec. 8, 2016  EIP Pharma, ... has obtained proof-of-mechanism for neflamapimod (previously code named ... Phase 2a clinical trials that demonstrated significant Alzheimer,s ... 302 (12-week treatment) and Study 303 (6-week treatment) ... Trials in Alzheimer,s Disease (CTAD) scientific conference in ...
Breaking Medicine Technology:
Cached News: